Eliem Therapeutics Inc (ELYM)
7.84
-0.36
(-4.39%)
USD |
NASDAQ |
May 21, 16:00
7.86
+0.02
(+0.26%)
After-Hours: 20:00
Eliem Therapeutics Cash from Investing (TTM): 76.94M for March 31, 2024
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 76.94M |
| December 31, 2023 | 68.98M |
| September 30, 2023 | 46.51M |
| June 30, 2023 | 26.98M |
| March 31, 2023 | 44.27M |
| December 31, 2022 | 34.44M |
| Date | Value |
|---|---|
| September 30, 2022 | 12.11M |
| June 30, 2022 | -103.32M |
| March 31, 2022 | -119.00M |
| December 31, 2021 | -114.97M |
| September 30, 2021 | -98.84M |
| June 30, 2021 | 8.078M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-119.00M
Minimum
Mar 2022
76.94M
Maximum
Mar 2024
-9.818M
Average
19.55M
Median
Cash from Investing (TTM) Benchmarks
| Alpine Immune Sciences Inc | -86.47M |
| Candel Therapeutics Inc | -0.306M |
| Cyclacel Pharmaceuticals Inc | 0.00 |
| Lipocine Inc | 3.440M |
| GlycoMimetics Inc | -0.0266M |